Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 7/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6490024 | 0.90 | TP53 (0.39) | TP53LMNARAB9ASMN1; SMN2MAPT | |
| SCHEMBL6491900 | 0.89 | SMN1; SMN2 (0.58) | TP53LMNARAB9ASMN1; SMN2MAPT | |
| SCHEMBL6492522 | 0.88 | SMN1; SMN2 (0.47) | TP53LMNARAB9ASMN1; SMN2MAPT | |
| SCHEMBL6489500 | 0.88 | TP53 (0.49) | TP53LMNASMN1; SMN2MAPTMAPK1 | |
| SCHEMBL6501432 | 0.86 | ITGB1 (0.42) | TP53LMNAMGAT2 | |
| SCHEMBL6499119 | 0.85 | TP53 (0.45) | TP53LMNASMN1; SMN2MAPTMAPK1 | |
| SCHEMBL6488453 | 0.83 | TP53 (0.42) | TP53LMNASMN1; SMN2MAPTPOLB | |
| SCHEMBL6503252 | 0.83 | TRPV1 (0.47) | RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL6800702 | 0.81 | RAB9A (0.47) | TP53LMNARAB9ASMN1; SMN2MAPT | |
| SCHEMBL6498339 | 0.80 | SMN1; SMN2 (0.51) | TP53LMNARAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | TP53 3031/4885LMNA 629/4885RAB9A 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.